Bradanicline Explained

Bradanicline (INN,^[1] code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder.^[2] Phase I clinical trials were completed successfully, and it was in phase II trials.^[3]

In May 2011, AstraZeneca declined to exercise its right to license the compound.^[4] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.^[5] It was being studied for cognitive and memory enhancement.^[6]

Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late-2013.^[7] It was also discontinued for ADHD.

Notes and References

1. Web site: International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 73 . World Health Organization . 3 January 2017 . 68–9.
2. Web site: TC-5619 Cognitive Dysfunction in Schizophrenia . Catalyst Biosciences . https://web.archive.org/web/20080820060552/http://www.targacept.com/wt/page/tc_5619 . August 20, 2008 .
3. Drahl C . Rethinking Schizophrenia . Chemical & Engineering News . September 2008 . 86 . 37 . 38–40 . 10.1021/cen-v086n037.p038 .
4. News: Targacept retains full development rights for TC-5619 . Fierce Biotech . 2 May 2011 .
5. Web site: Targacept ends development of ADHD drug . Market Watch .
6. Web site: Statement on a Nonproprietary Name Adopted by the USAN Council . November 27, 2013 .
7. Web site: Bradanicline - Attenua . AdisInsight . Springer Nature Switzerland AG .